ABSTRACTS

PP50 Non-invasive fetal genotyping of RHCE C/c and E alleles in allo-immunized pregnant women: evaluation of a 7-year experience

PP56 Infectious complications of a novel tyrosine kinase inhibitor (ibrutinib) and correlation with immunological markers in patients with malignant hemopathies

PP61 A randomized, double-blind, placebo-controlled, phase 3 study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura

PP62 Treatment-free remission after TPO receptor agonists in adult itp patients in belgium

Should we measure DOACs?

At the time of the introduction of direct oral anticoagulants (DOACs) in the beginning of this century, episodic and routine monitoring of these drug concentrations was deemed unnecessary. Unlike oral vitamin K anticoagulation, DOACs showed predictable pharmacokinetics and pharmacodynamics. However, once in clinical practice it became clear that under specific circumstances predictability of drug concentrations was less than optimal. During his educational presentation, Prof Johathan Douxfils (Univeristy of Namur) provided some answers to the questions why, when, and how we should measure DOAC concentrations.

The new mechanism of autoimmunity is a HIT

Starting off the second day of the annual meeting of the BSTH, Andreas Greinacher (Greifswald, Germany) presented on the mechanism behind heparin-induced thrombocytopenia (HIT). A mechanism that is part of an evolutionary old defence mechanism against prokaryotic pathogens. However, when misdirected this pathway displays an until recently unknown mechanism of autoimmunity.

SHOULD WE MEASURE DOACS?